Showing 2 of 10 years of data. Sign up free for 3 years, or upgrade for full access.
View Plans2-year trend showing gross, operating, and net profit margins
Glenmark Pharmaceuticals Ltd.'s net profit margin of 7.9% in FY2025 reflects thin profitability, with operating margin at 14.0% and gross margin at 67.3%.
In FY 2025, Glenmark Pharmaceuticals Ltd. posted a gross margin of 67.3%, an operating margin of 14.0%, a net margin of 7.9%. Gross Margin = (Revenue - COGS) / Revenue; Operating Margin = EBIT / Revenue; Net Margin = Net Income / Revenue. Typical healthy ranges: Gross 20-40%, Operating 10-20%, Net 5-10%+. Consistent or improving margins indicate strong competitive positioning.
2-year trend showing revenue, gross profit, and net profit
Glenmark Pharmaceuticals Ltd.'s revenue grew 5.3% to 133.22B and net profit grew 173.0% to 10.47B YoY in FY2025, indicating moderate business momentum.
In FY 2025, Glenmark Pharmaceuticals Ltd.'s revenue grew by 5.3% year-over-year. Revenue is total income from operations. Gross Profit is revenue minus cost of goods. Net Profit is the bottom line after all expenses. Consistent growth across all three signals a healthy, expanding business.
2-year trend showing shareholder returns
Glenmark Pharmaceuticals Ltd.'s ROE of 11.8% in FY2025 indicates moderate shareholder returns.
In FY 2025, Glenmark Pharmaceuticals Ltd. reported an ROE of 11.8%. ROE = (Net Income / Shareholders' Equity) x 100. Measures how efficiently the company turns equity into profit. Above 15% is generally strong; above 25% is excellent. Very high ROE may signal high leverage — check alongside debt levels.
2-year trend comparing profitability with cash generation
Glenmark Pharmaceuticals Ltd.'s FCF/NI ratio of -1.51x in FY2025 indicates weak cash generation raising concerns about earnings quality.
In FY 2025, Glenmark Pharmaceuticals Ltd.'s free cash flow trailed net income. Free Cash Flow = Operating Cash Flow - Capital Expenditure. When FCF exceeds net income, it suggests high-quality, cash-backed earnings. Persistent gaps may indicate aggressive accounting or heavy capex needs.
2-year trend comparing profitability with cash from operations
Glenmark Pharmaceuticals Ltd.'s OCF/NI ratio of -0.79x in FY2025 indicates weak cash conversion raising concerns about earnings quality.
In FY 2025, Glenmark Pharmaceuticals Ltd.'s operating cash flow trailed net income. Operating Cash Flow is the actual cash from core operations. OCF exceeding net income signals strong cash collection. OCF trailing net income may indicate aggressive revenue recognition or working capital issues.
Measure a company's financial leverage, liquidity, and ability to meet financial obligations.
2-year trend showing short-term liquidity position
Glenmark Pharmaceuticals Ltd.'s current ratio of 1.56x in FY2025 indicates healthy short-term liquidity.
In FY 2025, Glenmark Pharmaceuticals Ltd. reported a current ratio of 1.56. Current Ratio = Current Assets / Current Liabilities. Measures short-term liquidity. A ratio of 1.5-3.0 is generally healthy; below 1.0 signals liquidity risk; above 3.0 may indicate underutilized assets.
2-year trend showing ability to service debt
Glenmark Pharmaceuticals Ltd.'s interest coverage ratio of 9.0x in FY2025 indicates comfortable debt servicing capacity.
In FY 2025, Glenmark Pharmaceuticals Ltd. reported an interest coverage ratio of 9.0x. Interest Coverage = EBIT / Interest Expense. Shows how many times operating profit covers interest payments. Above 5x is comfortable; below 1.5x signals potential difficulty servicing debt.
2-year trend showing financial leverage and capital structure
Glenmark Pharmaceuticals Ltd.'s debt-to-equity ratio of 0.28x in FY2025 reflects a conservative, low-leverage capital structure.
In FY 2025, Glenmark Pharmaceuticals Ltd. reported a debt-to-equity ratio of 0.28. Debt-to-Equity = Total Debt / Total Equity. Below 1.0 is conservative; 1.0-2.0 is moderate; above 2.0 indicates higher financial risk. Capital-intensive industries naturally carry higher ratios.
2-year trend showing total debt with year-over-year changes
Glenmark Pharmaceuticals Ltd.'s debt increased 100.9% YoY in FY2025 — rising leverage demands close monitoring.
In FY 2025, Glenmark Pharmaceuticals Ltd.'s total debt increased by 100.9% year-over-year. Total Debt includes short-term debt, long-term loans, debentures, and capital leases. YoY changes (shown as percentages) reveal whether the company is leveraging up or deleveraging.
Year-over-year change in diluted shares outstanding
Glenmark Pharmaceuticals Ltd.'s diluted shares remained virtually unchanged in FY2025.
Over 2 years (FY2024–FY2025), diluted shares remained essentially unchanged at 282.21M.
In FY 2025, Glenmark Pharmaceuticals Ltd.'s diluted shares increased by 0.0% year-over-year. Diluted Shares accounts for stock options, warrants, and convertibles. Positive YoY change means dilution (red); negative means buybacks (green). Consistent dilution above 5% annually is a red flag.
You're viewing 2 years of data. Upgrade to access 10 years of financial ratios, margins, and performance metrics.
Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: FY 2025